War in the Middle East: collateral damage The Lancet Oncology ++ + +...

Estimating the impact of scaling up workforce personnel on global cancer mortality from 2030 to 2050: a simulation-based analysis of 17 cancers and 18 personnel types Zachary J Ward, PhDa,b,c Send email to zward@hsph.harvard.edu ∙ Fabio Ynoe Moraes, MDe,f ∙ Prof Andrew M Scott, MDg,h,i,j ∙ Fernanda M Favoritok ∙ Prof Wil Ngwa, PhDl ∙ Prof Timothy R Rebbeck, PhDd,m ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00062-8/abstract?dgcid=raven_jbs_etoc_feature_lanonc Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC–ESTRO OligoCare consortium Prof Joachim Widder, MD PhDa Send email to joachim.widder@muv.ac.at ∙ Guus M Bol, MD PhDb,c ∙ Inga-Malin Simek, MDa ∙ Felix Ehret, MDd,e ∙ Hoda Abdel-Aty, FRCR MD[Res]f ∙ Selma Basicg ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00075-6/abstract?dgcid=raven_jbs_etoc_feature_lanonc War in the Middle East: collateral damage The Lancet Oncology https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00187-7/fulltext?dgcid=raven_jbs_etoc_email May 2026 Volume 27Number 5p527-648, e232-e270 https://www.thelancet.com/journals/lanonc/issue/vol27no5/PIIS1470-2045(26)X2004-6